Article Detail

Home > Article Detail
  • P-ISSN 1225-0163
  • E-ISSN 2288-8985

Article Contents

    Spectrofluorometric quantification of Clozapine in pharmaceutical formulations and human plasma

    Analytical Science and Technology / Analytical Science and Technology, (P)1225-0163; (E)2288-8985
    2022, v.35 no.1, pp.24-31
    https://doi.org/10.5806/AST.2022.35.1.24
    Ali Fahim Mohammed (Chemistry Department, College of Science, Babylon University & Al-mustaqbal University College)
    AN Alshirifi (Chemistry Department, College of Science, Babylon University)
    Kasim Hassan Kadhim (Chemistry Department, College of Science, Babylon University)
    • Downloaded
    • Viewed

    Abstract

    Herein, we present a simple, precise, accurate, and ultra-sensitive spectrofluorimetric method for estimation of clozapine (CLZ) in tablets and human plasma was developed and then validated. A highly fluorescent brown-yellowish fluorophore was formed (λex=469 nm, λemi=540 nm) as a nucleophilic substitution reaction occurred between CLZ and 4-chloro-7-nitro-2,1,3-benzoxadiazole (NBD-Cl) in alkaline mcllavine buffer (pH 9.0). Optimum values of experimental parameters were carefully determined and optimized. The calibration curve was rectilinear over the concentration range of 80-900 ng mL−1 with a linear correlation coefficient (r =0.9984). The LOD and LOQ were determined to be 14 ng mL−1 and 42 ng mL−1, respectively. The proposed approach has been used successfully to quantification of Clozapine in its commercial formulations and human plasma.

    keywords
    clozapine, NBD-Cl, spectrofluorimetric, human plasma


    Reference

    1

    1. M. W. Jann, Pharmacother. J. Hum. Pharmacol. Drug Ther., 11(3), 179-195 (1991).

    2

    2. M. G. Choc, F. Hsuan, G. Honigfeld, W. T. Robinson, L. Ereshefsky, M. L. Crismon, S. R. Saklad, J. Hirschowitz and R. Wagner, Pharm. Res., 7(4), 347-351 (1990).

    3

    3. M. A. Raggi, V. Pucci, F. Bugamelli and V. Volterra, J. AOAC Int., 84(2), 361-367 (2001).

    4

    4. A. Essali, N. A. H. Haasan, C. Li and J. Rathbone, Cochrane Database Syst. Rev., 2009(1), 1-174 (2009).

    5

    5. D. Siskind, L. McCartney, R. Goldschlager and S. Kisely, Br. J. Psychiatry, 209(5), 385-392 (2016).

    6

    6. P. B. Mitchell, in ‘Therapeutic drug monitoring of antidepressant and antipsychotic drugs’, Vol. 7, p257-275, Elsevier, 2020.

    7

    7. J. M. J. Alvir, J. A. Lieberman, A. Z. Safferman, J. L. Schwimmer and J. A. Schaaf, NEJM, 329(3), 162-167(1993).

    8

    8. F. Islam, D. Hain, D. Lewis, R. Law, L. Brown, J.-A. Tanner and D. J. Mueller, Biol. Psychiatry, 89(9), S341(2021).

    9

    9. N. Tunsirimas, P. Pariwatcharakul, S. Choovanichvong and W. Ratta-Apha, Asian J. Psychiatr., 41, 13-16(2019).

    10

    10. S. Rajagopal, in ‘Clozapine, agranulocytosis, and benign ethnic neutropenia’, The Fellowship of Postgraduate Medicine, 2005.

    11

    11. M. Hasegawa, P. A. Cola and H. Y. Meltzer, Neuropsychopharmacology, 11(1), 45-47 (1994).

    12

    12. M. Wiciński and M. M. Węclewicz, Curr. Opin. Hematol., 25(1), 22-28 (2018).

    13

    13. S. L. Gerson and H. Meltzer, Drug Safety, 7(1), 17-25(1992).

    14

    14. W. Ng, R. Kennar and J. Uetrecht, Chem. Res. Toxicol., 27(7), 1104-1108 (2014).

    15

    15. B. A. Sproule, C. A. Naranjo, K. E. Bremner and P. C. Hassan, Clin. Pharmacokinet., 33(6), 454-471 (1997).

    16

    16. U. A. Patil and B. Ghosh, Int. J. Pharm. Tech. Res., 1, 733-736 (2009).

    17

    17. https://go.drugbank.com/drugs/DB00363.

    18

    18. H. Ben-Yoav, S. E. Chocron, T. E. Winkler, E. Kim, D. L. Kelly, G. F. Payne and R. Ghodssi, Electrochim. Acta., 163, 260-270 (2015).

    19

    19. K. Farhadi and A. Karimpour, Anal. Sci., 23(4), 479-483 (2007).

    20

    20. U. Bondesson and L. H. Lindström, Psychopharmacology, 95(4), 472-475 (1988).

    21

    21. M. Rosland, P. Szeto, R. Procyshyn, A. M. Barr and K. M. Wasan, Drug Dev. Ind. Pharm., 33(10), 1158-1166(2007).

    22

    22. M. Raggi, F. Bugamelli, R. Mandrioli, D. De Ronchi and V. Volterra, Chromatographia, 49(1-2), 75-80 (1999).

    23

    23. Y. Liu, L. D. van Troostwijk and H. J. Guchelaar, Biomed. Chromatogr., 15(4), 280-286 (2001).

    24

    24. C. Wongsinsup, W. Taesotikul, S. Kaewvichit, S. Sangsrijan and S. Sangsrija, CMU. J. Nat. Sci., 9, 29-37 (2010).

    25

    25. E. Schulz, C. Fleischhaker and H. Remschmidt, Pharmacopsychiatry, 28(01), 20-25 (1995).

    26

    26. K. Manjunatha and V. Venkateshwarlu, Indian J. Pharm. Sci., 67(4), 448 (2005).

    27

    27. H. Weigmann, J. Bierbrauer, S. Härtter and C. Hiemke, Ther. Drug Monit., 19(4), 480-488 (1997).

    28

    28. E. Dural, G. MERGEN and T. SÖYLEMEZOĞLU, Turkish J. Pharm. Sci., 12(2), 177-186 (2015).

    29

    29. S. Mennickent, A. Sobarzo, M. Vega, C. G. Godoy and M. de Diego, J. Sep. Sci., 30(13), 2167-2172 (2007).

    30

    30. A. Avenoso, G. Facciolà, G. M. Campo, A. Fazio and E. Spina, J. Chromatogr. B Biomed. Appl., 714(2), 299-308 (1998).

    31

    31. A. M. Eldidamony, S. M. Hafeez and M. M. A. Hafez, Int. J. Pharm., 7(1), 178-184 (2015).

    32

    32. M. R. Fathi and D. Almasifar, IEEE Sens. J., 17(18), 6069-6076 (2017).

    33

    33. E. Reyhan, S. YILMAZ, S. YAĞMUR and Ö. T. YAYINTAŞ, J. Sci. Perspect., 1(2), 19-30 (2017).

    34

    34. K. A. Attia, A. El-Olemy, S. Ramzy, A. H. Abdelazim, M. A. Hasan, M. K. Omar and M. Shahin, Spectrochim. Acta A Mol. Biomol. Spectrosc., 244, Article 118871(2021).

    35

    35. Guideline, I. Q2 (R1): validation of analytical procedure:text and methodology. ICH, London 2005.

    36

    36. A. Ayman, A. M. Zeid, M. Wahba and E.-S. Yasser, Spectrochim. Acta A Mol. Biomol. Spectrosc., 238, Article 118447 (2020).

    상단으로 이동

    Analytical Science and Technology